Tobias Dreyer
Overview
Explore the profile of Tobias Dreyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
190
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lammert J, Dreyer T, Mathes S, Kuligin L, Borm K, Schatz U, et al.
JCO Precis Oncol
. 2024 Oct;
8:e2400478.
PMID: 39475661
Purpose: Rapidly expanding medical literature challenges oncologists seeking targeted cancer therapies. General-purpose large language models (LLMs) lack domain-specific knowledge, limiting their clinical utility. This study introduces the LLM system Medical...
2.
Liu Y, Gong W, Panoutsopoulou K, Singer-Cornelius T, Augustin K, Bronger H, et al.
Am J Cancer Res
. 2023 Jul;
13(6):2471-2487.
PMID: 37424802
Triple-negative breast cancer (TNBC) represents the most aggressive breast cancer subtype, associated with early metastasis and recurrence as well as poor patient outcome. TNBC does not or weakly respond to...
3.
Panoutsopoulou K, Magkou P, Dreyer T, Dorn J, Obermayr E, Mahner S, et al.
Eur J Cancer
. 2023 Jan;
180:134-145.
PMID: 36599181
Introduction: Despite recent advances in epithelial ovarian cancer (EOC) management, the highly heterogenous histological/molecular tumour background and patients' treatment response obstructs personalised prognosis and therapeutics. Herein, we have studied the...
4.
Panoutsopoulou K, Liu Y, Avgeris M, Dreyer T, Dorn J, Magdolen V, et al.
Clin Biochem
. 2022 Dec;
114:43-51.
PMID: 36502883
Objectives: In the era of precision medicine, the highly aggressive and heterogenous triple-negative breast cancer (TNBC) is still characterized by limited options to support personalized prognosis and guide therapeutic interventions....
5.
Goldhardt O, Freiberger R, Dreyer T, Willner L, Yakushev I, Ortner M, et al.
Alzheimers Dement
. 2022 Nov;
19(5):2117-2134.
PMID: 36396609
Introduction: Human herpes simplex virus 1 (HSV1) is discussed to induce amyloid-β (Aβ) accumulation and neurofibrillary tangles of hyperphosphorylated tau (pTau) in Alzheimer's disease (AD) in cell culture and animal...
6.
Guner G, Assfalg M, Zhao K, Dreyer T, Lahiri S, Lo Y, et al.
EMBO Mol Med
. 2022 Sep;
14(10):e16084.
PMID: 36069059
Fn14 is a cell surface receptor with key functions in tissue homeostasis and injury but is also linked to chronic diseases. Despite its physiological and medical importance, the regulation of...
7.
Panoutsopoulou K, Dreyer T, Dorn J, Obermayr E, Mahner S, Van Gorp T, et al.
Cancers (Basel)
. 2022 Jan;
14(1).
PMID: 35008188
Epithelial ovarian cancer (EOC) remains a highly-lethal gynecological malignancy, characterized by frequent recurrence, chemotherapy resistance and poor 5-year survival. Identifying novel predictive molecular markers remains an overdue challenge in the...
8.
Riedel M, Bronger H, Magdolen V, Dreyer T
Expert Rev Mol Diagn
. 2021 May;
21(6):535-545.
PMID: 33947310
Ovarian cancer is one of the deadliest malignancies among women worldwide. The lack of early diagnostic markers fuels an unfavorable prognosis as most patients are at an advanced stage when...
9.
Kryza T, Khan T, Lovell S, Harrington B, Yin J, Porazinski S, et al.
Nat Chem Biol
. 2021 Apr;
17(7):776-783.
PMID: 33859413
CUB domain-containing protein 1 (CDCP1) is an oncogenic orphan transmembrane receptor and a promising target for the detection and treatment of cancer. Extracellular proteolysis of CDCP1 by poorly defined mechanisms...
10.
Gong W, Zhu C, Liu Y, Muckenhuber A, Bronger H, Scorilas A, et al.
Am J Transl Res
. 2021 Apr;
13(3):1594-1606.
PMID: 33841682
Triple-negative breast cancer (TNBC) patients have the worst outcome among all breast cancer subtypes. In oral squamous carcinoma cells, miR-378 was reported to target the mRNA of kallikrein-related peptidase 4...